Name: UMIN ID:
Unique ID issued by UMIN | UMIN000016608 |
---|---|
Receipt number | R000019276 |
Scientific Title | Clinical Research on the efficacy evaluation and the biomarker of nivolumab to an advance malignant melanoma |
Date of disclosure of the study information | 2015/02/23 |
Last modified on | 2020/02/27 13:36:13 |
No. | Disposal | Last modified on | Item of update | |
---|---|---|---|---|
1 | Insert | 2015/02/23 16:40:23 | ||
2 | Update | 2015/02/23 17:01:19 | Acronym Acronym |
|
3 | Update | 2015/02/23 17:09:13 | Condition |
|
4 | Update | 2015/08/27 16:28:43 | Key inclusion criteria |
|
5 | Update | 2015/08/27 16:30:47 | Recruitment status |
|
6 | Update | 2015/08/28 13:28:10 | Organization Organization Category of Funding Organization Research ethics review |
|
7 | Update | 2015/08/28 13:29:05 | Date of protocol fixation Anticipated trial start date |
|
8 | Update | 2015/08/28 13:43:46 | Acronym Acronym |
|
9 | Update | 2016/02/23 11:28:47 | Nationality of Funding Organization |
|
10 | Update | 2016/02/29 13:19:08 | Organization Organization Category of Funding Organization Organization1 |
|
11 | Update | 2016/09/07 09:51:15 | Last name of lead principal investigator Last name of lead principal investigator Organization Organization Division name Division name Address Address Name of primary person or sponsor Organization Institutions |
|
12 | Update | 2017/08/28 14:01:31 | Last follow-up date |
|
13 | Update | 2018/01/11 11:16:37 | Recruitment status |
|
14 | Update | 2019/11/22 12:01:40 | Public title |
|
15 | Update | 2020/02/27 13:34:21 | 1st name of lead principal investigator Last name of lead principal investigator 1st name of lead principal investigator Last name of lead principal investigator Zip code Address Last name of contact person Last name of contact person Zip code Address Organization Organization Address Address Tel |
|
16 | Update | 2020/02/27 13:35:38 | Number of participants that the trial has enrolled |
|
17 | Update | 2020/02/27 13:36:13 | Date of IRB |